Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
Authors:
- Raffaele PezzilliRaffaele Pezzilli
- Dario FabbriDFDario Fabbri
- Massimiliano M. CorsiMassimiliano M. Corsi
- Andrea ImbrognoAIAndrea Imbrogno
- Alessandra BarassiABAlessandra Barassi
- Antonio M. Morselli-LabateAMAntonio M. Morselli-Labate
- Riccardo CasadeiRCRiccardo Casadei
- Roberto CorinaldesiRCRoberto Corinaldesi
- 17 March 2011
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (6) , 1047-1051
Abstract
Background: The aim of the study was to evaluate the circulating concentrations of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor-D (VEGF-D) and endostatin in patients with intraductal papillary mucinous neoplasm (IPMN), and in those with ductal adenocarcinomas. Methods: Sixty patients (32 males, 28 females, mean age 69.3±11.3 years) were enrolled: 31 (51.7%) had IPMNs and 29 (48.3%) had histologically confirmed pancreatic adenocarcinomas. Thirty blood donors were also studied as controls. In all study subjects, the concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin were determined using enzyme-linked immunosorbent assays. Results: Serum concentrations of VEGF, VEGF-D, and VEGFR-2 were significantly higher in patients with pancreatic ductal adenocarcinoma and those with IPMNs compared with healthy subjects, while endostatin was significantly higher only in patients with pancreatic ductal adenocarcinoma compared with healthy subjects. Within the group of patients, VEGFR-2 was significantly higher in patients with ductal adenocarcinoma compared to those with IPMNs. The sensitivity and the specificity of VEGFR-2 in differentiating patients with ductal adenocarcinomas from those with IPMN at a cut-off range of 4003–4034 pg/mL was 86.2% and 54.8%, respectively. Conclusions: IPMNs have serum VEGFR-2 concentra-tions different from those in patients with ductal adenocarcinomas. However, serum VEGFR-2 cannot be routinely utilized to differentiate IPMNs from pancreatic ductal adenocarcinomas.Keywords
This publication has 9 references indexed in Scilit:
- Significance of phospho‐vascular endothelial growth factor receptor‐2 expression in pancreatic cancerCancer Science, 2010
- Serum determination of CA 19-9 in diagnosing pancreatic cancer: An obituaryDigestive and Liver Disease, 2010
- Management of Mucin-Producing Cystic Neoplasms of the PancreasThe Oncologist, 2009
- Expression pattern and circulating levels of endostatin in patients with pancreas cancerInternational Journal of Cancer, 2008
- Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinomaCancer Detection Prevention, 2007
- Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammationJournal of Gastroenterology, 2007
- Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the ClinicCurrent Medicinal Chemistry, 2006
- Usefulness of Plasma Vascular Endothelial Growth Factor in the Diagnosis of Pancreatic CarcinomaPancreas, 2005
- Serum interleukin-6, interleukin-8, andβ 2-Microglobulin in early assessment of severity of acute pancreatitis comparison with serum C-reactive proteinDigestive Diseases and Sciences, 1995